An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

NCT02985398 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine Disorder

Interventions

BIOLOGICAL: ALD403 (Eptinezumab)

Sponsor

Alder Biopharmaceuticals, Inc.